VKTX

Insider Trades

Name	Value	Action	Price	Current Price
Aubuchon Neil WilliamChief Commercial Officer $150k4.5k shares BuyMar 10, 2026 $33.50 --
Lian BrianDirector, Officer: President & CEO $4.3M132.5k shares SellJan 5, 2026 $32.29 --
Lian BrianDirector, Officer: President & CEO $1.8M53.3k shares SellJan 5, 2026 $33.38 --
Lian BrianDirector, Officer: President & CEO $1.4M41.3k shares SellJan 5, 2026 $34.22 --
Mancini MariannaChief Operating Officer $1.0M32k shares SellJan 5, 2026 $32.29 --
Zante GregChief Financial Officer $1.0M32k shares SellJan 5, 2026 $32.30 --

News

zacks.comViking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Knowzacks.comJun 17

fool.comIs Viking Therapeutics Stock Going to $100?fool.comJun 12

prnewswire.comViking Therapeutics Announces Appointment of Hubert C. Chen, M.D.prnewswire.comJun 11

zacks.comViking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Knowzacks.comJun 10

fool.comWhy 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188%fool.comJun 10

Trade VKTX

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.

CEO: Brian Lian
IPO Date: Apr 28, 2015

Market Data

Open: $30.69
High: $31.55
Low: $30.16
Volume: 2.6M
Avg Volume: 2.2M
52W High: $43.15
52W Low: $22.96

Valuation

Market Cap: $3.5B
Enterprise Value: $3.4B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-279M
Revenue: $0
Net Income: $-360M
Cash: $166M
Debt: $137k

Events

EarningsJul 29

EPS est. -1.21